dual anti-CLL1/anti-CD38 CAR T-cell therapy (Gracell Biotechnologies)

N/A

Report date: 2025/06/11 10:16:09

Base Information

Drug Namedual anti-CLL1/anti-CD38 CAR T-cell therapy (Gracell Biotechnologies)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocytes stimulantsC-Type lectin domain family 12 member A modulatorsImmunostimulants +[4]

TargetsLymphocyte differentiation antigen CD38C-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesGracell Biotechnologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesGracell Biotechnologies Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A